PMID- 34406397
OWN - NLM
STAT- Publisher
LR  - 20240220
IS  - 1759-4685 (Electronic)
IS  - 1674-2788 (Print)
IS  - 1759-4685 (Linking)
VI  - 13
IP  - 8
DP  - 2021 Aug 18
TI  - Multi-omics profiling: the way towards precision medicine in metabolic diseases.
PG  - 576-93
LID - mjab051 [pii]
LID - 10.1093/jmcb/mjab051 [doi]
AB  - Metabolic diseases including type 2 diabetes mellitus (T2DM), non-alcoholic fatty 
      liver disease (NAFLD), and metabolic syndrome (MetS) are alarming health burdens 
      around the world, while therapies for these diseases are far from satisfying as 
      their etiologies are not completely clear yet. T2DM, NAFLD, and MetS are all 
      complex and multifactorial metabolic disorders based on the interactions between 
      genetics and environment. Omics studies such as genetics, transcriptomics, 
      epigenetics, proteomics, and metabolomics are all promising approaches in 
      accurately characterizing these diseases. And the most effective treatments for 
      individuals can be achieved via omics pathways, which is the theme of precision 
      medicine. In this review, we summarized the multi-omics studies of T2DM, NAFLD, 
      and MetS in recent years, provided a theoretical basis for their pathogenesis and 
      the effective prevention and treatment, and highlighted the biomarkers and future 
      strategies for precision medicine.
CI  - (c) The Author(s) 2021. Published by Oxford University Press on behalf of Journal 
      of Molecular Cell Biology, IBCB, SIBS, CAS.
FAU - Hu, Cheng
AU  - Hu C
AD  - Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, 
      Shanghai Clinical Center for Diabetes, Shanghai Jiao Tong University Affiliated 
      Sixth People's Hospital, Shanghai 200233, China.
AD  - Institute for Metabolic Disease, Fengxian Central Hospital, The Third School of 
      Clinical Medicine, Southern Medical University, Shanghai 201499, China.
FAU - Jia, Weiping
AU  - Jia W
AD  - Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, 
      Shanghai Clinical Center for Diabetes, Shanghai Jiao Tong University Affiliated 
      Sixth People's Hospital, Shanghai 200233, China.
LA  - eng
PT  - Journal Article
DEP - 20210818
PL  - United States
TA  - J Mol Cell Biol
JT  - Journal of molecular cell biology
JID - 101503669
SB  - IM
PMC - PMC8697344
OTO - NOTNLM
OT  - biomarkers
OT  - metabolic syndrome
OT  - multi-omics profiling
OT  - non-alcoholic fatty liver disease
OT  - precision medicine
OT  - type 2 diabetes mellitus
EDAT- 2021/08/19 06:00
MHDA- 2021/08/19 06:00
PMCR- 2021/08/18
CRDT- 2021/08/18 12:28
PHST- 2021/04/08 00:00 [received]
PHST- 2021/06/19 00:00 [revised]
PHST- 2021/06/21 00:00 [accepted]
PHST- 2021/08/18 12:28 [entrez]
PHST- 2021/08/19 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2021/08/18 00:00 [pmc-release]
AID - 6354369 [pii]
AID - mjab051 [pii]
AID - 10.1093/jmcb/mjab051 [doi]
PST - aheadofprint
SO  - J Mol Cell Biol. 2021 Aug 18;13(8):576-93. doi: 10.1093/jmcb/mjab051.